USD
GBP
CNY
EUR
INR
JPY
MYR
ZAR
KRW
THB
Analysis of the United States Molecular Imaging Equipment and Radiopharmaceuticals Market, Forecast to 2023
Analysis of the United States Molecular Imaging Equipment and Radiopharmaceuticals Market, Forecast to 2023
Technology Advances and New Radiopharmaceuticals Maintain the Industry on a Growth Track
RELEASE DATE
06-Mar-2017
06-Mar-2017
REGION
North America
North America
Research Code: K0A6-01-00-00-00
SKU: HC02728-NA-MR_19502
$4,950.00
Special Price $3,712.50 save 25 %
In stock
SKU
HC02728-NA-MR_19502
Description
Molecular imaging can easily be described as the next frontier of medical imaging. In an era of value-based reimbursement, molecular imaging is set to play a significant role in quicker diagnosis, more accurate disease staging, and selection of targeted treatments. Launch of new radiopharmaceuticals across clinical areas other than cardiology and oncology such as neurology and orthopedics is also expected to drive greater adoption of molecular imaging as part of clinical care pathways.
However, molecular imaging continues to face several challenges, notably the high cost of molecular imaging modalities and image scans, competition from lower cost modalities such as CT and MRI, and concerns over future supply of Tc-99m, a key SPECT radiopharmaceutical used for cardiac scans. This study analyzes existing trends in the hybrid molecular imaging and diagnostic radiopharmaceuticals markets with an emphasis on understanding strategies employed by market participants to address these myriad challenges. It also assesses both these markets in the context of changing regulatory and reimbursement policies in order to provide future market trends. This analysis will be critical in helping market participants create long-term viable strategies in order to remain competitive and ensure continuous innovation.
This deliverable assesses future trends in molecular imaging equipment revenues as well as growth in the number of unit shipments over the next few years. This will provide value to market participants that design and manufacture molecular imaging equipment. Market participants will also be provided insights on recent industry and technology trends that are shaping the molecular imaging market. Radiopharmaceutical manufacturers will be provided with key insights on the evolving usage trends of workhorse FDG and Tc-99m radiopharmaceuticals and the increasing adoption of new radiopharmaceuticals across new clinical areas. Companies that are in the process of developing software to improve quantitation accuracy, lower dosages, and reduce scan times for both PET and SPECT will be provided with key insights on how the molecular imaging market is growing as well as the factors that are required to facilitate greater adoption of PET and SPECT technologies.
RESEARCH: INFOGRAPHIC
This infographic presents a brief overview of the research, and highlights the key topics discussed in it.Click image to view it in full size
Table of Contents
Research Methodology
Scope of This Study
Key Findings
Market Engineering Measurements—PET/CT
Market Engineering Measurements—SPECT/CT
Market Engineering Measurements—PET/MR
Key Findings
Market Engineering Measurements—PET
Market Engineering Measurements—SPECT
Scope of the Study—Molecular Imaging
Scope of the Study—Radiopharmaceuticals
Molecular Imaging—Segmentation
Molecular Imaging—Definition
Shift in Focus from Standalone to Hybrid Imaging
Radiopharmaceuticals—Definitions
Segmentation of Radiopharmaceuticals
Distribution of Radiopharmaceuticals
US Radiopharmacy Facility Landscape 2016
Market Drivers
Improvements in Quantitation Accuracy
Role of Molecular Imaging in Personalized Medicine
Molecular Imaging Entering Into New Therapeutic Areas
Market Restraints
Affordability of Hybrid Modalities Will Remain Key Issue
Consolidations of Healthcare Providers
Changing Hospital Procurement Models
Market Engineering Measurements
Unit Shipment Forecast
Revenue Forecast
Trend Analysis
Market Share
Market Share Analysis
Market Engineering Measurements
Unit Shipment Forecast
Revenue Forecast
Trend Analysis
Market Share
Market Share Analysis
Market Engineering Measurements
Unit Shipment Forecast
Revenue Forecast
Trend Analysis
Market Share
Market Share Analysis
Analysis of Hybrid Molecular Imaging Products
Actively Marketed PET/CT Products in 2016
Actively Marketed PET/MR Products in 2016
Actively Marketed SPECT/CT Products in 2016
Digital PET—The Next Chapter in Nuclear Imaging
GE Healthcare—Key Technology Trends
GE Debuts DiscoveryTM MI PET/CT at SNMMI 2016
Launch of Discovery IQ PET/CT by GE
GE Launches First General Purpose Digital SPECT/CT
Siemens Debuts Mobile Biograph Horizon PET/CT
Siemens Debuts Latest Version of syngo.via
NeuSoft
Toshiba America Medical Systems
Molecular Dynamics
UltraSPECT
Upgradeability and Intra Modality Competition
Nuclear Medicine Physicians Face Employment Challenges
Technology Trends—PET/CT & SPECT/CT
Industry Trends—Advancements in Brain Imaging Using SPECT
Industry Trends—PET Scanning and Alzheimer’s Disease
Industry Trends—CMS Approves Funding for PET Amyloid Study
Industry Trends—Myocardial Perfusion Imaging: PET vs. SPECT
Market Drivers
Development of New Radiopharmaceuticals
Adopting a Cyclotron-based Approach
Mo-99 Production—Key Challenges and Potential Solutions
Market Restraints
Pricing and Reimbursement of Tc-99m—Key Challenges
High Entry Barriers Limit the Number of Participants
Market Engineering Measurements
Procedure Forecast
Revenue Forecast
Trend Analysis
Market Share
Market Share Analysis
Market Engineering Measurements
Procedure Forecast
Revenue Forecast
Trend Analysis
Market Share
Market Share Analysis
Analysis of PET and SPECT Radiopharmaceuticals
Key Market Participants and Main Product Lines
Siemens PETNET
IBA Molecular
Ionetix
Jubilant Draximage Develops Rubidium Generator
Northstar Medical Isotopes to Produce Mo-99
FDA Approves Gallium 68 Dotatate Kit—NETSPOT
FDA Approves Axumin PET Radiopharmaceutical
Axumin—Safety and Efficacy Parameters
CMS Rejection of NaF—18 PET Scan Reimbursement
Cardiac PET Perfusion Agents Industry—A Snapshot
Role of Radiopharmaceuticals in Oncology Clinical Trials
18F-CFA—The Next Frontier in Cancer Treatment
New PET Tracers for Clinical Use in Oncology
The Last Word—3 Big Predictions: Molecular Imaging
The Last Word—3 Big Predictions: Radiopharmaceuticals
Legal Disclaimer
Glossary of Terms—Molecular Imaging
Glossary of Terms—Radiopharmaceuticals
Market Engineering Methodology
Reimbursement of Procedures Involving Use of Radiopharmaceuticals and Molecular Imaging Modalities
Reimbursed Radiopharmaceuticals Billing Codes
List of Figures- 1. Total Molecular Imaging Equipment Market: Key Market Drivers, US, 2017–2023
- 2. Total Molecular Imaging Equipment Market: Key Market Restraints, US, 2017–2023
- 3. PET/CT Equipment Segment: Market Engineering Measurements, US, 2016
- 4. SPECT/CT Equipment Segment: Market Engineering Measurements, US, 2016
- 5. PET/MR Equipment Segment: Market Engineering Measurements, US, 2016
- 6. Total Radiopharmaceuticals Market: Key Market Drivers, US, 2017–2023
- 7. Total Radiopharmaceuticals Market: Key Market Restraints, US, 2017–2023
- 8. PET Radiopharmaceuticals Segment: Market Engineering Measurements, US, 2016
- 9. SPECT Radiopharmaceuticals Segment: Market Engineering Measurements, US, 2016
List of Charts- 1. PET/CT Equipment Segment: Market Engineering Measurements, US, 2016
- 2. SPECT/CT Equipment Segment: Market Engineering Measurements, US, 2016
- 3. PET/MR Equipment Segment: Market Engineering Measurements, US, 2016
- 4. PET Radiopharmaceuticals Segment: Market Engineering Measurements, US, 2016
- 5. SPECT Radiopharmaceuticals Segment: Market Engineering Measurements, US, 2016
- 6. PET/CT Equipment Segment: Unit Shipment Forecast, US, 2013–2023
- 7. PET/CT Equipment Segment: Revenue Forecast, US, 2013–2023
- 8. PET/CT Equipment Segment: Percent of Sales, US, 2016
- 9. SPECT/CT Equipment Segment: Unit Shipment Forecast, US, 2013-2023
- 10. SPECT/CT Equipment Segment: Revenue Forecast, US, 2013–2023
- 11. SPECT/CT Equipment Segment: Percent of Sales, US, 2016
- 12. PET/MR Equipment Segment: Unit Shipment Forecast, US, 2013–2023
- 13. PET/MR Equipment Segment: Revenue Forecast, US, 2013–2023
- 14. PET/MR Equipment Segment: Percent of Sales, US, 2016
- 15. PET Radiopharmaceuticals Segment: Procedure Forecast, US, 2013–2023
- 16. PET Radiopharmaceuticals Segment: Revenue Forecast, US, 2013-2023
- 17. PET Radiopharmaceuticals Segment: Percent of Sales, US, 2016
- 18. SPECT Radiopharmaceuticals Segment: Procedure Forecast, US, 2013–2023
- 19. SPECT Radiopharmaceuticals Segment: Revenue Forecast, US, 2013–2023
- 20. SPECT Radiopharmaceuticals Segment: Percent of Sales, US, 2016
Popular Topics
Molecular imaging can easily be described as the next frontier of medical imaging. In an era of value-based reimbursement, molecular imaging is set to play a significant role in quicker diagnosis, more accurate disease staging, and selection of targeted treatments. Launch of new radiopharmaceuticals across clinical areas other than cardiology and oncology such as neurology and orthopedics is also expected to drive greater adoption of molecular imaging as part of clinical care pathways.
However, molecular imaging continues to face several challenges, notably the high cost of molecular imaging modalities and image scans, competition from lower cost modalities such as CT and MRI, and concerns over future supply of Tc-99m, a key SPECT radiopharmaceutical used for cardiac scans. This study analyzes existing trends in the hybrid molecular imaging and diagnostic radiopharmaceuticals markets with an emphasis on understanding strategies employed by market participants to address these myriad challenges. It also assesses both these markets in the context of changing regulatory and reimbursement policies in order to provide future market trends. This analysis will be critical in helping market participants create long-term viable strategies in order to remain competitive and ensure continuous innovation.
This deliverable assesses future trends in molecular imaging equipment revenues as well as growth in the number of unit shipments over the next few years. This will provide value to market participants that design and manufacture molecular imaging equipment. Market participants will also be provided insights on recent industry and technology trends that are shaping the molecular imaging market. Radiopharmaceutical manufacturers will be provided with key insights on the evolving usage trends of workhorse FDG and Tc-99m radiopharmaceuticals and the increasing adoption of new radiopharmaceuticals across new clinical areas. Companies that are in the process of developing softwa
| No Index | No |
|---|---|
| Podcast | No |
| Table of Contents | | Research Methodology~ || Research Methodology~ || Scope of This Study~ | Executive Summary—Molecular Imaging~ || Key Findings~ || Market Engineering Measurements—PET/CT~ || Market Engineering Measurements—SPECT/CT~ || Market Engineering Measurements—PET/MR~ | Executive Summary—Radiopharmaceuticals~ || Key Findings~ || Market Engineering Measurements—PET~ || Market Engineering Measurements—SPECT~ | Market Overview~ || Scope of the Study—Molecular Imaging~ || Scope of the Study—Radiopharmaceuticals~ || Molecular Imaging—Segmentation~ || Molecular Imaging—Definition~ || Shift in Focus from Standalone to Hybrid Imaging ~ || Radiopharmaceuticals—Definitions~ || Segmentation of Radiopharmaceuticals ~ || Distribution of Radiopharmaceuticals ~ || US Radiopharmacy Facility Landscape 2016~ | Drivers and Restraints—Total Molecular Imaging Equipment Market~ || Market Drivers~ ||| Improved quantitation accuracy makes molecular imaging more reliable~ ||| Molecular imaging will play an increasingly larger role in personalized medicine~ ||| Advances in molecular imaging technologies~ || Improvements in Quantitation Accuracy~ || Role of Molecular Imaging in Personalized Medicine~ || Molecular Imaging Entering Into New Therapeutic Areas~ || Market Restraints~ ||| Increasing cost of hybrid molecular imaging modalities~ ||| Mergers and acquisitions between hospitals and other hospitals~ ||| Changing procurement practices by hospitals~ || Affordability of Hybrid Modalities Will Remain Key Issue~ || Consolidations of Healthcare Providers~ || Changing Hospital Procurement Models~ | PET/CT Equipment Segment~ || Market Engineering Measurements~ || Unit Shipment Forecast~ || Revenue Forecast~ || Trend Analysis~ || Market Share~ || Market Share Analysis~ | SPECT/CT Equipment Segment~ || Market Engineering Measurements~ || Unit Shipment Forecast~ || Revenue Forecast~ || Trend Analysis~ || Market Share~ || Market Share Analysis~ | PET/MR Equipment Segment~ || Market Engineering Measurements~ || Unit Shipment Forecast~ || Revenue Forecast~ || Trend Analysis~ || Market Share~ || Market Share Analysis~ | Key Products and Participants~ || Analysis of Hybrid Molecular Imaging Products~ || Actively Marketed PET/CT Products in 2016~ || Actively Marketed PET/MR Products in 2016~ || Actively Marketed SPECT/CT Products in 2016~ | Latest Trends Among the Big Three Competitors—Philips Healthcare~ || Digital PET—The Next Chapter in Nuclear Imaging~ | GE Healthcare~ || GE Healthcare—Key Technology Trends~ || GE Debuts DiscoveryTM MI PET/CT at SNMMI 2016~ || Launch of Discovery IQ PET/CT by GE~ || GE Launches First General Purpose Digital SPECT/CT~ | Siemens Healthineers~ || Siemens Debuts Mobile Biograph Horizon PET/CT~ || Siemens Debuts Latest Version of syngo.via~ | Companies to Look Out For~ || NeuSoft~ || Toshiba America Medical Systems~ || Molecular Dynamics~ || UltraSPECT~ | Other Issues Impacting Growth Of Molecular Imaging~ || Upgradeability and Intra Modality Competition~ || Nuclear Medicine Physicians Face Employment Challenges~ | Key Technology and Industry Trends~ || Technology Trends—PET/CT & SPECT/CT~ || Industry Trends—Advancements in Brain Imaging Using SPECT~ || Industry Trends—PET Scanning and Alzheimer’s Disease~ || Industry Trends—CMS Approves Funding for PET Amyloid Study~ || Industry Trends—Myocardial Perfusion Imaging: PET vs. SPECT~ | Drivers and Restraints—Total Radiopharmaceuticals Market~ || Market Drivers~ ||| Development of new PET and SPECT~ ||| Greater adoption of cyclotron-based approaches~ ||| Reactor-based supply of Mo-99~ || Development of New Radiopharmaceuticals~ || Adopting a Cyclotron-based Approach~ || Mo-99 Production—Key Challenges and Potential Solutions~ || Market Restraints~ ||| Pricing of Tc-99m is per unit dose and not by amount~ ||| High entry barriers are limiting the number of market participants~ || Pricing and Reimbursement of Tc-99m—Key Challenges~ || High Entry Barriers Limit the Number of Participants~ | PET Radiopharmaceuticals Segment~ || Market Engineering Measurements~ || Procedure Forecast~ || Revenue Forecast~ || Trend Analysis~ || Market Share~ || Market Share Analysis~ | SPECT Radiopharmaceuticals Segment~ || Market Engineering Measurements~ || Procedure Forecast~ || Revenue Forecast~ || Trend Analysis~ || Market Share~ || Market Share Analysis~ | Key Products and Participants~ || Analysis of PET and SPECT Radiopharmaceuticals~ || Key Market Participants and Main Product Lines~ | Key Companies to Look Out For~ || Siemens PETNET~ || IBA Molecular~ || Ionetix~ | Key Industry Trends~ || Jubilant Draximage Develops Rubidium Generator~ || Northstar Medical Isotopes to Produce Mo-99~ || FDA Approves Gallium 68 Dotatate Kit—NETSPOT~ || FDA Approves Axumin PET Radiopharmaceutical~ || Axumin—Safety and Efficacy Parameters~ || CMS Rejection of NaF—18 PET Scan Reimbursement~ || Cardiac PET Perfusion Agents Industry—A Snapshot~ | Role of New Radiopharmaceuticals in Oncology~ || Role of Radiopharmaceuticals in Oncology Clinical Trials ~ || 18F-CFA—The Next Frontier in Cancer Treatment~ || New PET Tracers for Clinical Use in Oncology~ | The Last Word~ || The Last Word—3 Big Predictions: Molecular Imaging~ || The Last Word—3 Big Predictions: Radiopharmaceuticals~ || Legal Disclaimer~ | Appendix~ || Glossary of Terms—Molecular Imaging~ || Glossary of Terms—Radiopharmaceuticals~ || Market Engineering Methodology~ | Medicare Hospital Outpatient Prospective Payment System (HOPPS)~ || Reimbursement of Procedures Involving Use of Radiopharmaceuticals and Molecular Imaging Modalities~ || Reimbursed Radiopharmaceuticals Billing Codes |
| List of Charts and Figures | 1. Total Molecular Imaging Equipment Market: Key Market Drivers, US, 2017–2023~ 2. Total Molecular Imaging Equipment Market: Key Market Restraints, US, 2017–2023~ 3. PET/CT Equipment Segment: Market Engineering Measurements, US, 2016~ 4. SPECT/CT Equipment Segment: Market Engineering Measurements, US, 2016~ 5. PET/MR Equipment Segment: Market Engineering Measurements, US, 2016~ 6. Total Radiopharmaceuticals Market: Key Market Drivers, US, 2017–2023~ 7. Total Radiopharmaceuticals Market: Key Market Restraints, US, 2017–2023~ 8. PET Radiopharmaceuticals Segment: Market Engineering Measurements, US, 2016~ 9. SPECT Radiopharmaceuticals Segment: Market Engineering Measurements, US, 2016~| 1. PET/CT Equipment Segment: Market Engineering Measurements, US, 2016~ 2. SPECT/CT Equipment Segment: Market Engineering Measurements, US, 2016~ 3. PET/MR Equipment Segment: Market Engineering Measurements, US, 2016~ 4. PET Radiopharmaceuticals Segment: Market Engineering Measurements, US, 2016~ 5. SPECT Radiopharmaceuticals Segment: Market Engineering Measurements, US, 2016~ 6. PET/CT Equipment Segment: Unit Shipment Forecast, US, 2013–2023~ 7. PET/CT Equipment Segment: Revenue Forecast, US, 2013–2023~ 8. PET/CT Equipment Segment: Percent of Sales, US, 2016~ 9. SPECT/CT Equipment Segment: Unit Shipment Forecast, US, 2013-2023~ 10. SPECT/CT Equipment Segment: Revenue Forecast, US, 2013–2023~ 11. SPECT/CT Equipment Segment: Percent of Sales, US, 2016~ 12. PET/MR Equipment Segment: Unit Shipment Forecast, US, 2013–2023~ 13. PET/MR Equipment Segment: Revenue Forecast, US, 2013–2023~ 14. PET/MR Equipment Segment: Percent of Sales, US, 2016~ 15. PET Radiopharmaceuticals Segment: Procedure Forecast, US, 2013–2023~ 16. PET Radiopharmaceuticals Segment: Revenue Forecast, US, 2013-2023~ 17. PET Radiopharmaceuticals Segment: Percent of Sales, US, 2016~ 18. SPECT Radiopharmaceuticals Segment: Procedure Forecast, US, 2013–2023~ 19. SPECT Radiopharmaceuticals Segment: Revenue Forecast, US, 2013–2023~ 20. SPECT Radiopharmaceuticals Segment: Percent of Sales, US, 2016~ |
| Author | Tanvir Jaikishen |
| Industries | Healthcare |
| WIP Number | K0A6-01-00-00-00 |
| Is Prebook | No |